Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, Petyt G, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Azulay JP, Tison F, Destée A, Vidailhet M, Rascol O, Dujardin K, Defebvre L, Bordet R, Sablonnière B, Devos D; Parkgait-II Study Group. Moreau C, et al. Among authors: devedjian jc. Brain. 2015 May;138(Pt 5):1271-83. doi: 10.1093/brain/awv063. Epub 2015 Mar 23. Brain. 2015. PMID: 25805645 Free PMC article. Clinical Trial.
Intracerebroventricular dopamine for Parkinson's disease.
Devos D, Devedjian JC, Moreau C. Devos D, et al. Among authors: devedjian jc. Oncotarget. 2017 Jul 11;8(28):45034-45035. doi: 10.18632/oncotarget.17596. Oncotarget. 2017. PMID: 28484085 Free PMC article. No abstract available.
Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R. Devos D, et al. Among authors: devedjian jc. Antioxid Redox Signal. 2014 Jul 10;21(2):195-210. doi: 10.1089/ars.2013.5593. Epub 2014 Feb 6. Antioxid Redox Signal. 2014. PMID: 24251381 Free PMC article. Clinical Trial.
Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
Moreau C, Rolland AS, Pioli E, Li Q, Odou P, Barthelemy C, Lannoy D, Demailly A, Carta N, Deramecourt V, Auger F, Kuchcinski G, Laloux C, Defebvre L, Bordet R, Duce J, Devedjian JC, Bezard E, Fisichella M, Devos D. Moreau C, et al. Among authors: devedjian jc. Neurobiol Dis. 2020 Jun;139:104846. doi: 10.1016/j.nbd.2020.104846. Epub 2020 Mar 20. Neurobiol Dis. 2020. PMID: 32205254 Free article.
Iron as a therapeutic target for Parkinson's disease.
Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D; FAIRPARK-II study group. Moreau C, et al. Among authors: devedjian jc. Mov Disord. 2018 Apr;33(4):568-574. doi: 10.1002/mds.27275. Epub 2018 Jan 30. Mov Disord. 2018. PMID: 29380903 Review. No abstract available.
54 results